Skip to main content

Table 2 Demographic and clinical characteristics at initiation of combination antiretroviral therapy by regimena

From: Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

  Overall Sample Ontario & Quebec Sub-analysis
Total
N = 2013
Atazanavir
N = 1791
Darunavir
N = 222
p Atazanavir
N = 544
Darunavir
N = 183
p
Demographics
 Age 40 (33–47) 40 (33–47) 40 (32–46) 0.25 38 (32–45) 39 (32–46) 0.49
  < 35 601 (30%) 521 (29%) 80 (36%) 0.03 189 (35%) 69 (38%) 0.02
 35–44 746 (37%) 680 (38%) 66 (30%)   217 (40%) 53 (29%)  
  ≥ 45 666 (33%) 590 (33%) 76 (34%)   138 (25%) 61 (33%)  
 Male 1632 (81%) 1439 (81%) 193 (87%) 0.02 434 (80%) 162 (89%) <.01
Gender & MSM
 Female 373 (19%) 344 (19%) 29 (13%) <.0001 110 (20%) 21 (11%) <.01
 MSM 764 (38%) 646 (36%) 118 (53%)   293 (54%) 113 (62%)  
 Male, not MSM 479 (24%) 451 (25%) 28 (13%)   93 (17%) 22 (12%)  
 Missing 397 (20%) 350 (20%) 47 (21%)   48 (9%) 27 (15%)  
Race
 White 531 (26%) 492 (27%) 39 (18%) <.001 146 (27%) 34 (19%) <.0001
 Black 128 (6%) 117 (7%) 11 (5%)   84 (15%) 11 (6%)  
 Aboriginal Peoples 109 (5%) 101 (6%) 8 (4%)   11 (2%) 7 (4%)  
 Other 145 (7%) 133 (7%) 12 (5%)   41 (8%) 9 (5%)  
 Missing 1100 (55%) 948 (53%) 152 (68%)   262 (48%) 122 (67%)  
Injection drug use
 No 1207 (60%) 1053 (59%) 154 (69%) <.0001 426 (78%) 142 (78%) 0.03
 Yes 542 (27%) 521 (29%) 21 (9%)   59 (11%) 11 (6%)  
 Missing 264 (13%) 217 (12%) 47 (21%)   59 (11%) 30 (16%)  
Endemic countryb
 No 537 (27%) 406 (23%) 131 (59%) <.0001 406 (75%) 131 (72%) 0.02
 Yes 99 (5%) 80 (4%) 19 (9%)   80 (15%) 19 (10%)  
 Missing 1377 (68%) 1305 (73%) 72 (32%)   58 (11%) 33 (18%)  
Province
 British Columbia 1286 (64%) 1247 (70%) 39 (18%) <.0001 -- --  
 Ontario 355 (18%) 264 (15%) 91 (41%)   264 (49%) 91 (50%) 0.78
 Quebec 372 (18%) 280 (16%) 92 (41%)   280 (51%) 92 (50%)  
Clinical
Hepatitis C
 No 1349 (67%) 1168 (65%) 181 (82%) <.0001 449 (83%) 155 (85%) 0.75
 Yes 559 (28%) 530 (30%) 29 (13%)   71 (13%) 20 (11%)  
 Missing 105 (5%) 93 (5%) 12 (5%)   24 (4%) 8 (4%)  
CD4 count (cells/mm3) 220 (120–330) 220 (120–320) 280 (130–370) <.01 230 (149–310) 286 (130–370) <.01
<200 869 (43%) 795 (44%) 74 (33%) <.001 214 (39%) 60 (33%) <.0001
200–349 693 (34%) 620 (35%) 73 (33%)   234 (43%) 60 (33%)  
350–499 287 (14%) 237 (13%) 50 (23%)   69 (13%) 45 (25%)  
≥500 164 (8%) 139 (8%) 25 (11%)   27 (5%) 18 (10%)  
Log 10 (VL copies/mL) 4.91 (4.41–5.11) 4.90 (4.42–5.05) 4.94 (4.36–5.44) 0.03 4.82 (4.35–5.26) 4.90 (4.26–5.39) 0.43
VL ≥ 100,000 copies/mL 881 (44%) 780 (44%) 101 (45%) 0.58 209 (38%) 77 (42%) 0.38
Year of cART initiation 2009 (2007–2010) 2008 (2006–2010) 2011 (2010–2011) <.0001 2008 (2007–2009) 2010 (2010–2011) <.0001
2003–2006 474 (24%) 473 (26%) 1 (0%) <.0001 121 (22%) 1 (1%) <.0001
2007–2009 799 (40%) 767 (43%) 32 (14%)   307 (56%) 32 (17%)  
2010–2012 740 (37%) 551 (31%) 189 (85%)   116 (21%) 150 (82%)  
First NRTIs
 3TC/ABA 499 (25%) 441 (25%) 58 (26%) <.0001 259 (48%) 53 (29%) <.0001
 3TC/TDF 285 (14%) 284 (16%) 1 (0%)   36 (7%) 1 (1%)  
 FTC/TDF 1172 (58%) 1009 (56%) 163 (73%)   230 (42%) 129 (70%)  
 Other 57 (3%) 57 (3%) 0 (0%)   19 (3%) 0 (0%)  
Follow up
 Years of Follow up 3.10 (1.45–5.16) 3.50 (1.63–5.38) 1.48 (0.69–2.25) <.0001 3.73 (2.20–5.32) 1.68 (0.86–2.46) <.0001
 VLs per year 4.67 (3.61–6.21) 4.68 (3.63–6.16) 4.50 (3.55–6.56) 0.71 3.88 (3.12–4.76) 4.32 (3.44–5.76) <.001
 0–3 274 (14%) 246 (14%) 28 (13%) 0.43 121 (22%) 26 (14%) <.001
 3–6 1187 (59%) 1062 (59%) 125 (56%)   358 (66%) 115 (63%)  
  > 6 552 (27%) 483 (27%) 69 (31%)   65 (12%) 42 (23%)  
  1. MSM men who have sex with men, VL viral load, cART combination antiretroviral therapy, NRTI nucleoside reverse transcriptase, 3TC lamivudine, ABC abacavir, TDF tenofovir, FTC emtricitabine
  2. a Medians (IQRs) are presented for continuous variables and frequencies (percent) for categorical variables
  3. b Indicates patients who have immigrated to Canada from a country with a high prevalence of HIV